New drug combo aims to stop breast cancer from coming back
NCT ID NCT03285412
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This Phase 2 trial is testing whether adding the drug ribociclib (Kisqali) to standard hormone therapy can improve outcomes for people with early-stage ER-positive breast cancer. The study involves 120 participants and focuses on clearing cancer DNA from the blood. The goal is to find a more effective way to prevent the cancer from returning.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ribociclib (Kisqali) plus endocrine therapy
What this could lead to
If successful, this could lead to a more effective treatment plan for early-stage ER+ breast cancer, potentially reducing the risk of recurrence.
What could go wrong
This is a Phase 2 trial with only 120 participants, so results may not apply to everyone. Side effects from ribociclib can include fatigue, nausea, and low blood cell counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Mass General/North Shore Cancer Center
Danvers, Massachusetts, 01923, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02214, United States